Amanin contains a cyclic peptide architecture featuring tightly constrained backbone geometry. Its noncanonical residues contribute to structural rigidity and resistance to unfolding. Researchers explore its molecular-recognition properties and conformational stability. Applications include toxin-analogue modeling, structural biology, and constrained-peptide research.
CAT No: R2683
CAS No:21150-21-0
Synonyms/Alias:AMANIN;Amanine;UNII-VIW95I76GY;VIW95I76GY;21150-21-0;HSDB 3457;DTXSID70895849;BRN 1070214;alpha-Amanitin, 1-L-aspartic acid-4-(2-mercapto-L-tryptophan)-;9,18-(Iminoethaniminoethaniminoethaniminomethano)pyrrolo(1',2':8, 9)(1,5,8,11,14)thiatetraaza cyclooctadecino(18,17-b)indole-6-acetic acid, 1,2,3,5,6,7,8,9,10,12,17,18,19,20,21,22,23,23a-octadecahydro-29-sec-butyl-21-(2,3-dihydroxy-1-methylpropyl)-2-hydroxy-5,8,20,23,24,27,30,33-octaoxo-, 11-oxide;9,18-(Iminoethaniminoethaniminoethaniminomethano)pyrrolo(1',2':8,9)(1,5,8,11,14)thiatetraazacyclooctadecino(18,17-b)indole-6-acetic acid, 1,2,3,5,6,7,8,9,10,12,17,18,19,20,21,22,23,23a-octadecahydro-29-sec-butyl-21-(2,3-dihydroxy-1-methylpropyl)-2-hydroxy-5,8,20,23,24,27,30,33-octaoxo-, 11-oxide;2-((1S,4S,8R,10S,13S,16S,34S)-34-((2S)-butan-2-yl)-13-((2R,3R)-3,4-dihydroxybutan-2-yl)-8-hydroxy-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo(14.12.11.06,10.018,26.019,24)nonatriaconta-18(26),19,21,23-tetraen-4-yl)acetic acid;2-(34-(butan-2-yl)-8,22-dihydroxy-13-(3-hydroxybutan-2-yl)-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonaazapentacyclo(14.12.11.06,10.018,26.019,24)nonatriaconta-18(26),19,21,23-tetraen-4-yl)acetic acid;2-[(1S,4S,8R,10S,13S,16S,34S)-34-[(2S)-butan-2-yl]-13-[(2R,3R)-3,4-dihydroxybutan-2-yl]-8-hydroxy-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19,21,23-tetraen-4-yl]acetic acid;2-[34-(butan-2-yl)-8,22-dihydroxy-13-(3-hydroxybutan-2-yl)-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonaazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19,21,23-tetraen-4-yl]acetic acid;.ALPHA.-AMANITIN, 1-L-ASPARTIC ACID-4-(2-MERCAPTO-L-TRYPTOPHAN)-;DTXCID801325348;CYCLO(L-.ALPHA.-ASPARTYL-4-HYDROXY-L-PROLYL-(R)-4,5-DIHYDROXY-L-ISOLEUCYL-2-MERCAPTO-L-TRYPTOPHYLGLYCYL-L-ISOLEUCYLGLYCYL-L-CYSTEINYL) CYCLIC (4->8)-SULFIDE (R)-S-OXIDE;alphaAmanitin, 1Laspartic acid4(2mercaptoLtryptophan);1-L-aspartic acid-4-(2-mercapto-L-tryptophan)-alpha-amanitin;9,18 (Iminoethaniminoethaniminoethaniminomethano)pyrrolo(1',2':8, 9)(1,5,8,11,14)thiatetraaza cyclooctadecino(18,17b)indole 6acetic acid, 1,2,3,5,6,7,8,9,10,12,17,18,19,20,21,22,23,23aoctadecahydro29secbutyl21(2,3dihydroxy1methylpropyl)2hydroxy5,8,20,23,24,27,30,33octaoxo, 11oxide;CYCLO(L-ALPHA-ASPARTYL-4-HYDROXY-L-PROLYL-(R)-4,5-DIHYDROXY-L-ISOLEUCYL-2-MERCAPTO-L-TRYPTOPHYLGLYCYL-L-ISOLEUCYLGLYCYL-L-CYSTEINYL) CYCLIC (4->8)-SULFIDE (R)-S-OXIDE;
1. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
4. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More